In the CTLA4 insufficiency model, treatment with anti-IL4-antibody and knockout of IL4Rα did not prevent inflammation but severed its link with the initiation of tumorigenesis (Miska et al., 2018), suggesting that therapies targeting type 2 inflammation may be useful in promoting anti-cancer immunity or cancer prevention as well. The gene discussed is IL4R; the disease is cancer.